Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01212328
Other study ID # UTRN 022342347-29072010248
Secondary ID
Status Recruiting
Phase N/A
First received September 6, 2010
Last updated September 2, 2011
Start date October 2010
Est. completion date June 2014

Study information

Verified date September 2011
Source Public Health Foundation of India
Contact Kavita Singh, MSc.
Phone +91-11-26850118
Email kavita@ccdcindia.org
Is FDA regulated No
Health authority United States: Institutional Review Board, Emory UniversityIndia: Institutional Review Board, Public Health Foundation of India
Study type Interventional

Clinical Trial Summary

Background: Cardiovascular diseases (CVD) are currently the leading cause of death globally and Asian Indians will account for between 40-60% of the global CVD burden within the next 10-15 years. Risk factor control and preventive care are effective in reducing CVD events and mortality. The greatest gains in CVD prevention have been seen when early and target-driven interventions address multiple risk factors together. However, achieving control of even individual risk factors (blood glucose, blood pressure, or blood lipid targets) is poor, globally. Quality improvement schemes, like the proposed intervention, have shown promise in high-income countries, but are untested in South Asia; a region with a population at extraordinarily high CVD risk.

Objective: To test whether a clinic-based case management intervention (consisting of guidelines based treatment, care coordinator assistance and decision support software) to reduce cardiovascular disease (CVD) risk among Type 2 diabetes patients in South Asia, is more effective and sustainable compared to existing care.

Trial subjects and methods: The study will involve a total of 1120 patients attending 8 established out-patient clinics in South Asia (140 patients at each clinic). Patients enrolled in the trial will be randomly assigned to either the control (existing care) or the intervention group and will be followed up for an average of 30 months. The total trial duration is about 3.5 years, from mid-August 2010 to December 31, 2013.


Recruitment information / eligibility

Status Recruiting
Enrollment 1120
Est. completion date June 2014
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Both
Age group 35 Years and older
Eligibility Inclusion Criteria:

1. Age 35 years and older

2. Confirmed diagnosis of diabetes based on documented evidence from oral glucose tolerance test or two venous fasting blood sugar levels or known diabetes patient on medication or insulin

3. Poor glycemic control (as evidenced by HbA1c >=8.0%) and one or both of: dyslipidemia [Low density Lipoprotein (LDL) >=130 mg/dl] or systolic hypertension [Systolic Blood Pressure (SBP) >=140 mmHg], irrespective of lipid- or BP-lowering medication use, respectively

4. Receiving diabetes care in the same clinic for at least 3 months OR even earlier if in the investigator's assessment the patient is likely to follow-up regularly as required by the protocol.

5. Willingness to consent to randomization.

Exclusion Criteria:

Individuals will be excluded from participation if any of the following are present during screening:

1. Known type 1 diabetes mellitus

2. Diabetes secondary to chronic pancreatitis

3. Pregnant OR trying to become pregnant OR of child-bearing potential and not actively practicing birth control (including natural methods)

4. Evidence of pre-existing well-controlled blood glucose, blood pressure or LDL-cholesterol (as evidenced by HbA1c < 7.0%, SBP < 130 mmHg, LDL-cholesterol < 100 mg/dl [LDL-cholesterol < 70 mg/dl with history of CVD event]) obtained from screening within a period not exceeding 28 days (4 weeks) prior to randomization

5. Documented cardiovascular event (coronary revascularization, stroke, MI, unstable angina) in past 12 months

6. Current symptomatic Congestive Heart Failure (CHF) or New York Heart Association (NYHA) Class 3 or 4 effort intolerance

7. Documented non-diabetic kidney disease OR pre-existing end -stage renal disease (on renal replacement therapy [dialysis or transplant])

8. Transaminase >3 times upper limit of normal OR active liver disease within past 2 years

9. Malignancy or life-threatening disease with death probable in 4 years

10. Any current medication (e.g. long-term steroids, protease inhibitors) that, in the opinion of the site investigator, would interfere with participant's diabetic status and follow-up

11. Any condition or circumstance that is unrelated to diabetes progression, that in the opinion of the site investigator would interfere with the participant's diabetic status and follow-up: including (but not limited to) other endocrinopathy [adrenal, pituitary], Tuberculosis (TB) patient on treatment, psychiatric illness or cognitive impairment, alcohol or drug abuse, history of organ transplant, Body Mass index (BMI) >= 45 kg/m2

12. On an investigational drug in the last 3 months

13. Currently participating in a clinical trial

14. No fixed address or contact details

15. Plans to move in the next 3 years

16. A member of the participant's household is currently in the trial

17. Inability or unwillingness of individual or legal guardian /representative to give written informed consent

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Other:
Care Coordinator + Decision Support Software
Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
Usual care
Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.

Locations

Country Name City State
India Bangalore Endocrinology and Diabetes Research Centre, #35, 5th Cross,Malleswaram Circle, Bangalore, Karnataka
India Osmania General Hospital, 2nd Floor, Golden Jubilee Block, Afzalgunj, Hyderabad
India Endocrine Division, Department of Medicine, Goa Medical College, Bambolim Goa
India Topiwala National Medical College & BYL Nair Ch. Hospital, Dr. A. L. Nair Road, Mumbai Central, Mumbai
India Amrita Institute of Medical Sciences Kochi Kerala
India Public Health Foundation of India New Delhi Delhi
India Diabetes Research Centre & MV Hospital for Diabetes, No 4 West Madha Church Street, Royapuram Chennai
India Department of Endocrinology, CARE Hospital, Road No 1, Banjara Hills, Hyderabad,
India St. John's Medical College & Hospital, Sarjapur Road, Koramangala, Bangalore
Pakistan Department of CHS, The Aga Khan, University, P.O. BOx. 3500 Stadium, Road, Karachi

Sponsors (6)

Lead Sponsor Collaborator
Public Health Foundation of India Aga Khan University, All India Institute of Medical Sciences, New Delhi, Madras Diabetes Research Foundation, Chennai, National Heart, Lung, and Blood Institute (NHLBI), United Health Group, USA

Countries where clinical trial is conducted

India,  Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multiple CVD risk factor control targets The study has one primary outcome of interest, multiple CVD risk factor control targets: at least two targets including Hemoglobin A1c (HbA1c) < 7.0% and at least one of: Blood Pressure (BP) < 130/80 mmHg or Low Density Lipoprotein (LDL)-cholesterol < 100 mg/dl (LDL cholesterol < 70 mg/dl for those with history of CVD event) 42 months after randomization Yes
Secondary Single risk factor control of at least one target either HbA1c or blood pressure or LDL-Cholesterol Single risk factor control
absolute 10% point greater proportion of participants in the intervention group achieving good glycemic control (HbA1c < 7%)
systolic BP < 130 and diastolic BP < 80 mmHg
LDL-cholesterol < 100 mg/dl, < 70 mg/dl for those with history of CVD event)
42 months after randomization Yes
Secondary The cost effectiveness analysis of the intervention compared to the usual care. 42 months after randomization No
Secondary Quality of life 42 months after randomization No
Secondary Prescriber and patient acceptability of the Digital Support software and care coordinator with management guidelines. 42 months after randomization No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A